Hematological Malignancies Clinical Trials

170 clinical trials for Hematological Malignancies across international registries, including 37 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant — RECRUITING · PHASE2
• To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers — RECRUITING · PHASE2
• Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies — RECRUITING · PHASE3
• A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies — RECRUITING · PHASE1
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE2
• A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies — RECRUITING · PHASE1
• A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies. — RECRUITING · PHASE2
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome — RECRUITING
• Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology — RECRUITING · NA
• Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation — RECRUITING · PHASE2
• A Clinical Study of HMPL-506 in Patients With Hematological Malignancies — RECRUITING · PHASE1
• The Study of ICP-248 in Patients With Mature B-cell Malignancies — RECRUITING · PHASE1
• 18F-Pentixafor PET in Hematologic Malignancies — RECRUITING
• National Longitudinal Cohort of Hematological Diseases (NICHE) - CART — RECRUITING
• Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study) — RECRUITING
• APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU — RECRUITING · NA
• A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging — RECRUITING · NA
• Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors — RECRUITING
• Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies — RECRUITING · NA
• LIGHTBEAM-U01 SUBSTUDY 01A: A PHASE 1/2 SUBSTUDY TO EVALUATE THE SAFETY AND EFFICACY OF ZILOVERTAMAB VEDOTIN IN PEDIATRIC AND YOUNG ADULT PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS — RECRUITING · PHASE1
• Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies — RECRUITING
• AN OPEN-LABEL, MULTICENTER, ROLL-OVER STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED SABATOLIMAB (MBG453) STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH SABATOLIMAB — RECRUITING
• PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE-3 BETA (GSK-3B) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY, IN PATIENTS WITH REFRACTORY HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS — RECRUITING · PHASE1
• Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT — RECRUITING · PHASE1
• A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK- 7684A (MK-7684 [VIBOSTOLIMAB] WITH MK-3475 [PEMBROLIZUMAB] COFORMULATION) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES — RECRUITING · PHASE2
• A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-1026 IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES — RECRUITING · PHASE2
• CANADIAN-LED IMMUNOTHERAPIES IN CANCER: CLIC-1901 FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CD19 POSITIVE HEMATOLOGIC MALIGNANCIES — RECRUITING
• "A PHASE 1/PHASE 2 CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF MK-4280 AND PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES." — RECRUITING · PHASE2
• A PHASE I/II STUDY OF NERATINIB IN PEDIATRIC PATIENTS WITH RELAPSED/ REFRACTORY SOLID TUMORS — RECRUITING · PHASE1
• A PHASE 1 MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY AND ANTITUMOR ACTIVITY OF MEDI7247 IN PATIENTS WITH SELECTED RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES — RECRUITING · PHASE1
• A PILOT STUDY OF ATEZOLIZUMAB (MPDL3280A) FOLLOWING ADOPTIVE CELL TRANSFER IN ACTIVE HEMATOLOGIC OR SOLID TUMOR MALIGNANCIES — RECRUITING
• A SINGLE ARM PHASE I/II OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF ANTI-MIHA T CELL LINES FOR THE TREATMENT OF PATIENTS WITH AML AND MDS WHO HAVE RELAPSED AFTER HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION — RECRUITING · PHASE1
• A PHASE 1A/1B DOSE ESCALATION AND EXPANSION TRIAL OF SINGLE-AGENT TTI-621, A NOVEL BIOLOGIC TARGETING CD47, IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES — RECRUITING · PHASE1
• AN EXPLORATORY, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF A TWO-DOSE REGIMEN OF ATIR101 IN PATIENTS WITH HEMATOLOGIC MALIGNANCY, WHO RECEIVED A CD34-SELECTED HSCT FROM A HAPLOIDENTICAL DONOR — RECRUITING
• A PHASE I OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY AND CLINICAL ACTIVITY OF THE ANTIBODY DRUG CONJUGATE GSK2857916 IN SUBJECTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND OTHER ADVANCED HEMATOLOGIC MALIGNANCIES EXPRESSING BCMA — RECRUITING · PHASE1
• A PHASE 1, DOSE-FINDING STUDY OF THE BROMODOMAIN (BD) INHIBITOR OTX015 IN HAEMATOLOGICAL MALIGNANCIES — RECRUITING · PHASE1
• Cologne Cohort of Neutropenic Patients (CoCoNut) — RECRUITING
• mNGS for IFD in Patients With Hematological Malignancies — NOT_YET_RECRUITING
• Dose-range Finding Treosulfan-based Conditioning — COMPLETED · PHASE1
• Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies — ACTIVE_NOT_RECRUITING · NA
• Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE2
• Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies — NOT_YET_RECRUITING · PHASE2
• Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe — NOT_YET_RECRUITING
• A PHASE 3, PROSPECTIVE, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF IGPRO20 IN SUBJECTS WITH SECONDARY IMMUNE DEFICIENCY DUE TO HEMATOLOGIC MALIGNANCIES TREATED WITH B-CELL TARGETING CHIMERIC ANTIGEN RECEPTOR T-CELL REDIRECTING THERAPIES — NOT_YET_RECRUITING · PHASE3
• Durvalumab and Tremelimumab for Pediatric Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — ACTIVE_NOT_RECRUITING · PHASE1
• Study of AZD9829 in CD123+ Hematological Malignancies — COMPLETED · PHASE1
• Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors — NOT_YET_RECRUITING · NA
• Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies — COMPLETED · PHASE3

Refine this search